Genentech: A strategic collaboration with BioNTech to develop individualized mRNA cancer therapies




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Genentech: A strategic collaboration with BioNTech to develop individualized mRNA cancer therapies
Released on: December 13, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Genentech's development pipeline continues to grow, with multiple promising projects in the following therapeutic focus areas: Oncology, Immunology, Neuroscience, Metabolism, and Infectious Disease.
  • Summary
  • Participants
  • Company
Genentech's development pipeline continues to grow, with multiple promising projects in the following therapeutic focus areas: Oncology, Immunology, Neuroscience, Metabolism, and Infectious Disease. Our clinical development pipeline includes monoclonal antibodies, small molecules, and antibody drug conjugates that address serious unmet medical needs.
Peter Fong serves as Associate Director of Oncology Business Development in the Genentech Partnering Group in South San Francisco. He is one of five on Genentech's Oncology Business Development team responsible for sourcing, screening, evaluating, and acquiring new therapeutics to build the company's oncology pipeline through in-licensing, M&A, partnering, and other business development activities. Oncology BD works closely with Genentech's leadership to establish the company's cancer strategy. Overall, Genentech Partnering is responsible for approximately half of Genentech's pipeline.
Genentech
Genentech Inc., a portmanteau of Genetic Engineering Technology, Inc., is a biotechnology corporation, which was founded in 1976 by venture capitalist Robert A. Swanson and biochemist Dr. Herbert Boyer.